Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASCO Gastrointestinal Cancers Symposium
Basel, Switzerland, January 23, 2020 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its oncology drug candidate derazantinib showed convincing activity in preclinical models of gastric cancer with FGFR genetic aberrations. The data will be presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO), which takes place January 23-25, 2020, in San Francisco, USA.
Dr. Laurenz Kellenberger, Basilea’s Chief Scientific Officer, said: “The preclinical data presented at the ASCO symposium show that derazantinib has the potential to provide clinical benefit in gastric cancer with FGFR genetic aberrations. Based on this convincing data we recently announced our intention to start a phase 1/2 study with derazantinib in patients with advanced gastric cancer in the third quarter of 2020.“The preclinical data were generated in patient-derived mouse models of biliary, gastric and colorectal cancer with FGFR gene fusions, mutations and amplifications. Derazantinib was well tolerated and led to strong responses in several animal models, particularly in gastric cancer models with FGFR2 gene fusions, where responses included complete tumor regression.
Gastric cancer is the fifth most common cancer worldwide and the third most lethal cancer type.1 Median survival rarely exceeds twelve months and the five-year-survival is less than 10%.2 Basilea estimates that there are approximately 190,000 new cases of gastric cancer per year in total across the EU top 5 countries, Japan and the U.S. FGFR genetic aberrations have been observed in about 10% of gastric cancers.3
A second abstract at the symposium provides an update on the ongoing registrational phase 2 study FIDES-01 (Fibroblast growth factor Inhibition with DErazantinib in Solid tumors) with derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients. The multicenter, multicohort open-label study is planned to enroll 43 patients with mutations or amplifications of the FGFR2 gene confirmed by next-generation sequencing. In addition, the study includes a cohort of approximately 100 patients with FGFR2 gene fusion positive iCCA. To date, FGFR inhibitors have demonstrated clinical activity in FGFR2 gene fusion-driven iCCA. Therefore, assessing the activity of derazantinib in FGFR2 gene mutations or amplifications is important to further define the full therapeutic potential of derazantinib in iCCA. Topline data for the cohort with FGFR2 gene fusion-positive patients and interim data for the cohort with FGFR2 gene mutations or amplifications are expected to become available in the second half of 2020.
Intrahepatic cholangiocarcinoma is a cancer originating from the biliary system. The age-adjusted incidence rate of iCCA in the United States has been increasing over the past decade and is currently estimated to be approximately 1.2 per 100,000.4 Patients are often diagnosed with advanced or metastatic disease that cannot be surgically removed. FGFR2 gene fusions have been reported in 13-22% of iCCA cases.5, 6 Current first-line standard of care is the chemotherapy combination of gemcitabine and platinum-derived agents. The prognosis for patients with advanced disease is poor, with a median survival of less than one year with chemotherapy.7 There is no proven effective treatment for patients who progress on first-line chemotherapy, thus there is a high unmet medical need.8
Derazantinib abstracts at the 2020 ASCO GI Cancers Symposium Thursday, 23 January 2020 – 12:00-1:30 p.m. PST Poster Session A -- The FGFR-inhibitor, derazantinib (DZB), is active in PDX-models of GI-cancer with specific aberrations in FGFR – Paul McSheehy, Felix Bachmann, Nicole Forster-Gross, Mahmoud El Shemerly, Mila Roceri, Laurenz Kellenberger, Heidi Lane; abstract 421, poster G10 Friday, 24 January 2020 – 12:00-1:30 p.m.PST Trial in Progress Poster Session B -- FIDES-01, a phase 2 study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A) – Walid L. Shaib, Christoph Gahlemann, Andrea Boncompagni, Silke Friedmann, Stephan Braun, Marc Engelhardt, Ghassan K. --------Abou-Alfa,-Mitexh-J.-Borad;-abstract-TPS597,-poster-P10-(ClinicalTrial.gov-identifier:-NCT03230318)---
For further information, please visit https://meetings.asco.org/gi/abstracts-posters.
Derazantinib (formerly ARQ 087) is an investigational orally administered small-molecule panFGFR kinase inhibitor with strong activity against FGFR1, 2, and 3.9 FGFR kinases are key drivers of cell proliferation, differentiation and migration. FGFR genetic aberrations, e.g. gene fusions, mutations or amplifications, have been identified as potentially important therapeutic targets for various cancers, including intrahepatic cholangiocarcinoma (iCCA), urothelial, breast, gastric and lung cancers.10 In these cancers, FGFR genetic aberrations are found in a range of 5% to 30%.11 Derazantinib also inhibits the colony-stimulating-factor-1-receptor kinase (CSF1R).9, 12 CSF1R-mediated signaling is important for the maintenance of tumor-promoting macrophages and therefore has been identified as a potential target for anti-cancer drugs.13 Pre-clinical data has shown that tumor macrophage depletion through CSF1R blockade renders tumors more responsive to T-cell checkpoint immunotherapy, including approaches targeting PD-L1/PD-1.14, 15 Derazantinib has demonstrated antitumor activity and a manageable safety profile in previous clinical studies, including a biomarker-driven phase 1/2 study in iCCA patients,16 and has received U.S. and EU orphan drug designation for iCCA. Basilea is currently conducting two clinical studies with derazantinib. The first study, FIDES-01, is a registrational phase 2 study in patients with inoperable or advanced iCCA. It comprises one cohort of patients with FGFR2 gene fusions and another cohort of patients with mutations or amplifications.17 The second study, FIDES-02, is a phase 1/2 study evaluating derazantinib alone and in combination with Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced urothelial cancer, including metastatic, or recurrent surgically unresectable disease, expressing FGFR genetic aberrations.18 Basilea in-licensed derazantinib from ArQule Inc, a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea’s website www.basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations +41 61 606 1102 email@example.com firstname.lastname@example.org -----------------------------------------------------
This press release can be downloaded from www.basilea.com.
1 F. M Johnston, M. Beckman. Updates on management of gastric cancer. Current Oncology Reports 2019 (21), 67
2 M. Orditura, G. Galizia, V. Sforza et al. Treatment of gastric cancer, World Journal of Gastroenterology 2014 (20), 1635-1649
3 A. Bass, V. Thorsson, I. Shmulevich et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014 (513), 202-209
4 S. K. Saha, A. X. Zhu, C. S. Fuchs et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. The Oncologist 2016 (21), 594-599
5 R. P. Graham, E. G. Barr Fritcher, E. Pestova et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Human Pathology 2014 (45), 1630-1638
6 A. Jain, M. J. Borad, R. K. Kelley et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precision Oncology 2018 (2), 1-12
7 A. Lamarca, D. H. Palmer, H. S. Wasa et al. ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. Journal of Clinical Oncology 2019 (37), supplement, abstract 4003
8 S. Sahu, W. Sun, Targeted therapy in biliary tract cancers – current limitations and potentials in the future. Journal of Gastrointestinal Oncology 2017 (8), 324-336
9 T. G. Hall, Y. Yu, S. Eathiraj et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS ONE 2016, 11 (9), e0162594
10 R. Porta, R. Borea, A. Coelho et al. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Critical Reviews in Oncology/Hematology 2017 (113), 256-267
11 T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer Research 2016 (22), 259-267
12 P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer. Molecular Cancer Therapeutics 2019 (18), 12 supplement, pp. LB-C12
13 M. A. Cannarile, M. Weisser, W. Jacob et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy of Cancer 2017, 5:53
14 Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models. Cancer Research 2014 (74), 5057-5069
15 E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proceedings of the National Academy of Science of the United States of America 2018 (115), E4041-E4050
16 V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120), 165-171. ClinicalTrials.gov identifier: NCT01752920
17 ClinicalTrials.gov identifier: NCT03230318
18 ClinicalTrials.gov identifier: NCT04045613. Tecentriq® is a registered trademark of Hoffmann-La Roche Ltd.
-- Press release (PDF)